Loading...
Loading...
Law Update
Quick note
Below is the official summary and the reference document preview. Use “Open PDF” for full screen view.
India's Directorate General of Trade Remedies (DGTR) has opened an anti-dumping investigation into imports of 6-Amino Penicillanic Acid, or 6-APA, from China PR and the European Union.
The initiation notification is dated 25 September 2026. The matter has been registered under SETU Case ID AD/OI/059/2026, with F. No. 6/58/2026-DGTR. The application was filed by Qule Pharma Private Limited.
The case matters because 6-APA is not an ordinary industrial chemical. It is an important pharmaceutical intermediate used in the production of several beta-lactam antibiotics.
At this stage, however, businesses should understand one point clearly: DGTR has started an investigation, it has not imposed anti-dumping duty through this notification.
The investigation will now examine whether the goods are being dumped, whether the domestic industry is facing material retardation because of those imports and whether there is a sufficient causal link between the two.
| Particular | Details |
| Authority | Directorate General of Trade Remedies |
| Department | Department of Commerce |
| Ministry | Ministry of Commerce and Industry |
| Document Type | Initiation Notification |
| Date | 25 September 2026 |
| File Number | F. No. 6/58/2026-DGTR |
| SETU Case ID | AD/OI/059/2026 |
| Product | 6-Amino Penicillanic Acid |
| Abbreviation | 6-APA |
| Subject Countries | China PR and European Union |
| Applicant | Qule Pharma Private Limited |
| Customs Tariff Heading | 2941 10 50 |
| Investigation Period | 1 April 2025 to 31 March 2026 |
| Injury Period | FY 2022-23, FY 2023-24, FY 2024-25 and POI |
| Main Issue | Alleged dumping and material retardation of domestic industry |
| Filing Platform | SETU Portal |
| Current Duty Status | No anti-dumping duty imposed through this initiation notification |
The notification begins the formal investigation. It does not settle the case.
6-APA is an organic chemical compound derived from Penicillin-G. In pharmaceutical manufacturing, it works as an intermediate used to produce several beta-lactam antibiotics.
The DGTR notification lists uses of 6-APA in:
It is also used in the manufacture of pharmaceutical products such as:
For pharmaceutical companies, this makes the investigation relevant beyond the importer itself. A change in the cost or availability of 6-APA can affect purchasing decisions further down the manufacturing chain.
Qule Pharma Private Limited approached DGTR with a claim that 6-APA imported from China PR and the European Union is being dumped in India.
The company has also argued that these imports are making it difficult for India's domestic 6-APA manufacturing base to establish itself properly.
The case is therefore not framed only around loss suffered by a mature, long-running industry. A central issue is whether imports are materially retarding the establishment of the domestic industry.
According to the applicant, its operating performance during the investigation period remained below what had been expected.
The allegations cover issues such as:
DGTR has not yet accepted these claims as final facts. It has found enough initial material to justify investigating them further.
The investigation is being conducted under the Customs Tariff Act, 1975 and the Customs Tariff (Identification, Assessment and Collection of Anti-Dumping Duty on Dumped Articles and for Determination of Injury) Rules, 1995.
These provisions lay down how India examines dumping complaints and when anti-dumping measures may be recommended.
Customs Tariff Act, 1975
Section 9A provides the legal basis for imposing anti-dumping duty where goods are exported to India at dumped prices, and the required legal conditions are met.
Starting an investigation does not automatically lead to duty.
DGTR first has to examine the evidence.
Anti-Dumping Rules, 1995
The Anti-Dumping Rules deal with matters such as:
The notification specifically refers to several provisions, including Rules 2(b), 5, 6, 7 and 13.
The Product Under Consideration, commonly called the PUC, is:
6-Amino Penicillanic Acid (6-APA).
DGTR has adopted Metric Tonnes (MT) as the unit of measurement.
The product is classifiable under:
Customs Tariff Heading 2941 10 50
The notification also contains an important qualification. The customs tariff heading is only indicative.
In other words, the legal scope of the investigation is based on the description of the product under consideration and is not controlled only by the tariff heading.
Product Scope Snapshot
| Item | Position in the Notification |
| Product | 6-Amino Penicillanic Acid |
| Abbreviation | 6-APA |
| Unit | Metric Tonnes |
| Customs Heading | 2941 10 50 |
| Tariff Classification | Indicative only |
| Countries Under Investigation | China PR and EU |
A dumping case does not compare two completely unrelated products. DGTR first needs to examine whether the product made in India is comparable with the product being imported.
The applicant stated that domestic 6-APA and imported 6-APA from China PR and the EU do not have any known material differences.
The notification records comparison on factors such as:
The goods are also considered technically and commercially substitutable.
For the purpose of opening the investigation, DGTR has therefore treated the Indian product as a like article to the subject imports.
The investigation covers imports originating in or exported from:
China PR
China is one of the two subject jurisdictions in the case.
European Union
The European Union is the second subject jurisdiction.
Businesses should not assume that all 6-APA imports, regardless of origin, are part of this case. The investigation is specifically concerned with the subject countries identified by DGTR.
DGTR will not examine the case on the basis of a few isolated shipments.
The notification defines a specific period for analysing dumping and a wider period for assessing injury.
Period of Investigation
1 April 2025 to 31 March 2026
This is a 12-month period.
Injury Investigation Period
The wider injury period covers:
the Period of Investigation.
Timeline
| Period | Relevance |
| FY 2022-23 | Injury analysis |
| FY 2023-24 | Injury analysis |
| FY 2024-25 | Injury analysis |
| 1 Apr 2025-31 Mar 2026 | Dumping POI + injury analysis |
The application was filed by Qule Pharma Private Limited.
The company stated that no other producer of the PUC currently exists in India and that it represents the entire domestic production of the subject goods.
The notification records that 6-APA was produced in India earlier, but domestic manufacturing had stopped.
Qule Pharma started production of the like article in FY 2024-25.
Based on the evidence available at the initiation stage, DGTR recorded that the applicant accounted for 100% of Indian domestic production.
A company filing an anti-dumping case must satisfy the requirements for representing the domestic industry.
DGTR has stated that Qule Pharma qualifies as the domestic industry within the meaning of Rule 2(b) and that its application meets the standing requirements under Rule 5(3).
There is, however, an interesting fact in this case.
Related entities had imported 6-APA.
The notification says that:
DGTR examined this point because links between a domestic producer and subject imports can become relevant when deciding domestic-industry status.
The Authority recorded that these imports were used in the manufacture of downstream products and were not imported for resale.
On that basis, DGTR considered that the related-party imports did not change Qule Pharma's character as a domestic producer.
Three concepts are central to the dumping analysis:
These sound technical, but the basic idea is easier to understand.
Normal Value
Normal value is the benchmark used for comparison with the export price.
Depending on the facts, it can be based on home-market prices, third-country prices, constructed value or another method permitted by the Anti-Dumping Rules.
Export Price
Export price refers to the price at which the goods are exported to India, after making relevant adjustments where required.
Dumping Margin
The dumping margin is broadly the difference between normal value and export price after making the required comparison.
A positive dumping margin can support a dumping allegation, but that alone does not settle an anti-dumping case.
DGTR must also examine injury and causal link.
The treatment of China has been explained separately in the notification.
The applicant relied on Article 15(a) of China's Accession Protocol and argued that Chinese producers should demonstrate that market-economy conditions prevail for the production and sale of the product concerned.
For initiation purposes, information on the cost and price of the PUC in a suitable market-economy third country was not available in the public domain.
Other third-country export-price information was also not available in a usable form.
The European Union could not simply be used as a benchmark because the EU itself is one of the jurisdictions accused of dumping in this case.
For the initiation stage, DGTR therefore determined normal value for China PR on another reasonable basis under Annexure I.
The Authority used the domestic industry's appropriately adjusted cost of production and made reasonable additions for selling, general and administrative expenses and profit.
This is an initiation-stage approach, not necessarily the final method that will remain unchanged throughout the proceeding.
The European Union has a separate analysis.
The applicant stated that it tried to obtain:
It could not identify a sufficiently credible source for those prices.
The applicant did provide information relating to raw-material and utility prices in Germany.
However, information on EU manufacturers' conversion costs and selling, general and administrative expenses was not available.
For initiation purposes, DGTR therefore considered a constructed normal value based on the domestic industry's adjusted production cost with reasonable additions for selling, general and administrative expenses and profit.
DGTR has used transaction-wise import data from DG Systems.
The CIF price reported for the product was considered, and adjustments were claimed for items such as:
inland freight.
The objective was to arrive at an ex-factory export price that could be compared with normal value at the same commercial level.
At the initiation stage, normal value and export price were compared at the ex-factory level.
DGTR recorded that the dumping margin was:
This finding gave DGTR enough prima facie basis to proceed with the investigation.
What the notification does not provide is equally important.
It does not state:
Those issues can only be settled after further investigation.
This is one of the more notable parts of the case.
The applicant is not simply saying that an established Indian industry has lost business.
It is arguing that dumped imports are preventing a domestic 6-APA industry from properly establishing itself.
According to the application, the company could not achieve the production and sales levels it had expected.
It also referred to:
Low Capacity Utilisation
The applicant claims that capacity utilisation remained low when compared with Indian demand.
Price Pressure
Subject imports were allegedly entering India at prices below the applicant's cost of sales.
The applicant says it had to reduce prices to compete with the landed price of imports.
Financial Performance
The application refers to:
Import Volume
DGTR has recorded, for initiation purposes, that imports from the subject countries were not negligible.
The notification further states that China PR and the EU accounted for virtually the entire volume of 6-APA imports during the POI.
On the evidence available at this stage, DGTR considered that there was sufficient prima facie material to investigate material retardation and causal link.
The easiest way to understand material retardation is to look at the stage of the Indian industry.
If an industry is already well established, an anti-dumping case may focus heavily on falling profits, market share, production or sales.
Here, the allegation is slightly different.
The domestic producer says it is trying to establish 6-APA manufacturing in India, but allegedly dumped imports are making that process materially difficult.
DGTR will therefore need to examine whether the domestic industry's failure to reach expected production, sales or utilisation levels can genuinely be linked to dumped imports.
It will also need to consider whether other factors could explain the performance.
That question has not yet been finally answered.
No.
This is probably the most important point for an importer reading the notification.
The 25 September 2026 document is an initiation notification.
It begins the investigation.
It does not impose an anti-dumping duty.
DGTR has started proceedings to determine:
An importer should therefore not automatically add an assumed anti-dumping duty to current transaction costs merely because this notification has been issued.
The applicant has asked DGTR to issue preliminary findings and recommend provisional anti-dumping duty under Rule 13.
That request has not been accepted through the initiation notification.
DGTR has said that the matter may be considered at an appropriate stage if and to the extent warranted.
Interested parties can also submit comments on this issue within the applicable timelines.
So, provisional duty is a possible future development in the proceeding, not a current duty created by this notification.
A DGTR investigation is not limited to the applicant.
Other parties affected by the case may also participate.
These can include:
Known producers/exporters, governments and known Indian importers/users are being informed separately so they can provide relevant information within the applicable timelines.
Interested parties are required to use the SETU Portal for filing.
The relevant case reference is: AD/OI/059/2026
All submissions should be made:
The notification also specifies the file format.
Narrative Submissions
These should be submitted in:
This sounds administrative, but it can affect whether the Authority can properly examine the information.
One common risk in anti-dumping matters is using the notification date as the starting point for every deadline.
That is not how this notification is worded.
Key Time Limits
| Requirement | Time Available | Trigger |
| Comments on PUC/PCN | 15 days | Transmission of relevant intimation letters |
| Questionnaire responses | 37 days | Transmission of intimation letters with NCV application/questionnaire |
| Confidentiality comments | 7 days | Transmission of intimation letters with NCV application/questionnaire |
| Extension request | At least 1 day before deadline | Original applicable deadline |
The 37-day filing period is linked to the date of transmission of the intimation letters, not automatically to 25 September 2026.
For an importer or exporter, this makes record-keeping around receipt of DGTR communication especially important.
Interested parties may comment on two important issues:
Scope of the Product Under Consideration
A business may have a genuine concern about whether a particular grade or specification falls inside or outside the proposed product scope.
Proposed PCN Methodology
PCN, or Product Control Number methodology, is used to organise product types for comparison during the investigation.
The notification gives interested parties 15 days from the relevant communication trigger to comment.
That period runs alongside the broader submission timeline.
Businesses should not assume that product-scope concerns can always be raised much later.
The notification also deals with a situation where DGTR later modifies the PUC or PCN methodology.
If a later change is different from what was proposed earlier, an additional 15 days may be given from the date of the modification notice.
This extension does not arise merely because an interested party wants more time.
It is tied specifically to a later PUC or PCN modification of the kind described in the notification.
Requests for further extension are generally not expected to be considered except in exceptional circumstances.
An extension request must also be filed on SETU at least one day before the original deadline.
Anti-dumping investigations often require companies to submit highly sensitive information.
This can include:
DGTR therefore permits confidentiality claims, but it also expects other interested parties to receive a meaningful non-confidential version.
Confidential Version (CV)
The confidential version contains information that is confidential by nature or information for which the party claims confidentiality.
A confidentiality claim should be supported with a proper reason.
Non-Confidential Version (NCV)
The NCV should broadly mirror the confidential submission while protecting sensitive information.
Depending on the nature of the data, confidential information may be:
The summary should still give another interested party a reasonable understanding of the substance of the information.
Correct Marking Matters
Every page should be clearly marked as:
Confidential or Non-Confidential
A submission that is not properly marked may be treated as non-confidential.
A weak non-confidential version can create a real procedural problem.
DGTR may:
A business participating in the case should therefore prepare the CV and NCV together rather than creating the NCV hurriedly at the end.
Yes.
The notification says that non-confidential versions filed by interested parties will be available to other interested parties through their SETU Portal logins.
This gives participants access to the non-confidential arguments and evidence placed on record by other parties.
Participation has practical consequences.
DGTR may treat a party as non-cooperative where it:
In such a situation, DGTR may proceed on the basis of the facts available on record and make recommendations to the Central Government accordingly.
The notification does not create a separate monetary fine for non-cooperation in this section.
The bigger concern is evidentiary: the Authority may have to decide the case without the missing party's full information.
For an Indian importer, there are two separate questions.
What Changes Right Now?
The initiation notification does not itself add anti-dumping duty to the import cost.
So there is no basis to say that every covered import has become more expensive simply because the investigation has opened.
What Should Importers Review?
Importers dealing in 6-APA from China PR or the EU should review:
Importers should also decide whether participation in the DGTR case is commercially important for them.
This is where proper import compliance services or specialised anti-dumping compliance services can be useful, particularly for businesses that have not previously responded to a trade-remedy investigation.
Exporters potentially have more at stake in the evidentiary part of the investigation.
DGTR questionnaires can require detailed information on:
The quality of the response matters.
Different annexures should reconcile with each other.
Sales data should align with financial information, and cost information should be supported by records.
Incomplete participation may result in DGTR relying on facts otherwise available.
An exporter working with an anti-dumping compliance consultant should therefore focus first on data accuracy and reconciliation rather than simply producing large quantities of documents.
A pharmaceutical company may be affected even if it does not directly import 6-APA.
Because 6-APA is used in manufacturing beta-lactam antibiotics, downstream companies should look at their exposure to the material.
Areas worth reviewing include:
Supplier Concentration
Alternative Suppliers
Are reliable alternative sources available in India or other countries?
Contract Terms
Do existing supply contracts allow price revisions if duties or other trade costs change?
Inventory
Would a future change in sourcing require longer inventory planning?
Costing
How sensitive are downstream product costs to changes in the price of 6-APA?
These are business-planning questions. They are not new legal duties created by the notification.
Potentially, yes, but the timing matters.
If Anti-Dumping Duty Is Recommended Later
Possible effects could include:
At the Current Stage
No such cost increase should be presented as an existing legal consequence of this notification.
The case is still under investigation.
| Stakeholder | Immediate Issue | What Should Be Checked | Main Risk |
| Indian Importer | Product exposure | Origin, supplier, import history | Missing filing opportunity |
| Chinese Exporter | DGTR questionnaire | Cost and sales records | Facts available if incomplete |
| EU Exporter | Investigation response | Export and cost data | Poor data reconciliation |
| Indian Producer | Injury claim | Production and financial evidence | Evidentiary gaps |
| Pharma User | Supply exposure | Procurement and contracts | Future sourcing/cost impact |
| Compliance Team | Procedure | SETU, deadlines, CV/NCV | Rejection or late filing |
Businesses involved in the case should avoid a few preventable errors.
Assuming Duty Has Already Started
The investigation is active, but no duty has been imposed through the initiation notification.
Counting 37 Days from 25 September 2026
The notification provides the link between the deadline for the response and the sending of the necessary intimation letters.
PUC Scope Ignored
Classifying the tariff is not sufficient in determining whether the product is in the PUC.
Submitting Non-Searchable Files
DGTR specifically requires searchable narrative files.
Preparing NCV at the Last Minute
The confidential and non-confidential versions should correspond properly.
Over-Claiming Confidentiality
A confidentiality claim needs adequate justification.
Missing Later DGTR Notices
The case can evolve through PCN notices, hearings, corrigenda or amendments.
The immediate response will depend on whether the business is an importer, exporter, producer or downstream user.
Still, a practical internal review can follow this order.
1. Map the Product
Confirm whether the material being imported or used is actually 6-APA covered by the PUC.
2. Check Origin and Export Route
Record:
3. Pull POI Data
Review transactions from:
1 April 2025 to 31 March 2026
4. Review the Wider Injury Period
Where relevant, keep data available for FY 2022-23, FY 2023-24 and FY 2024-25.
5. Decide Whether to Participate
An organization with significant commercial involvement needs to determine if formal involvement is required.
6. Get Listed on SETU Properly
Use: AD/OI/059/2026
7. Record the Date of Communication
Retain evidence of when the relevant intimation letter was transmitted.
This can determine the actual filing deadline.
8. Build the Questionnaire Response Around Source Records
Do not prepare figures first and try to find support later.
From:
9. Preparation of CV and NCV at the Same Time
It minimizes errors.
10. Always Monitor the Case
Monitor DGTR and SETU for new notices.
The investigation is now moving through its procedural stages.
Interested parties may first register, submit questionnaire responses and comment on PUC/PCN issues.
DGTR may then examine information relating to:
The notification specifically tells interested parties to monitor DGTR and SETU for further information relating to:
The applicant has also requested preliminary findings and provisional anti-dumping duty.
Whether DGTR issues such findings will depend on the course of the investigation.
The case can eventually move toward final findings, after which any duty-related action would depend on the applicable legal process.
No.
This is a decision to investigate, not a final decision on liability.
At this point:
That distinction should remain clear in procurement, compliance and public communication.
Anti-dumping cases usually have two legitimate commercial perspectives.
Domestic Producer's View
An Indian manufacturer may argue that it cannot establish sustainable production if imported goods are entering at unfairly low prices.
That is the issue Qule Pharma has raised.
Importer's View
Importers may depend on foreign supply because of pricing, availability, specification or customer demand.
A future duty can therefore affect procurement economics.
Downstream Manufacturer's View
Pharmaceutical manufacturers care about more than the price of the imported intermediate.
They also need:
The investigation will therefore be watched by businesses at several points in the supply chain.
Anti-dumping proceedings can become document-heavy very quickly.
Importers and exporters may need to work across customs data, commercial records, financial information, product descriptions and DGTR filing requirements at the same time.
Corpseed can support businesses through relevant anti-dumping compliance services and trade remedy compliance services, including:
1. PUC Applicability Review
Assessment of whether a product appears to fall within the notified scope.
2. Customs Classification Review
Review of the tariff classification used for the imported goods while keeping in mind that the DGTR product scope is not determined by tariff heading alone.
3. Import Data Review
Compilation and organisation of transaction data for the investigation period.
4. SETU Filing Support
Assistance with registration, case mapping and procedural filings.
5. Questionnaire Coordination
Support in organising questionnaire responses and related annexures.
6. CV and NCV Preparation Support
Review of confidential and non-confidential versions for consistency.
7. Confidentiality Review
Assistance in identifying sensitive information and preparing suitable non-confidential summaries.
8. Document Reconciliation
Checking whether sales, import, cost and financial data reconcile across different records.
9. Deadline Tracking
Monitoring relevant filing dates based on actual DGTR communications.
10. Import Compliance Support
Businesses that need wider import compliance services can also review product classification, origin records, import documentation and related customs requirements alongside the DGTR proceeding.
The role of a professional adviser is to help businesses prepare and present their information properly. No consultant can guarantee the dumping margin, duty rate or outcome of a DGTR investigation.
Document Preview
Embedded reference document
Related
Explore more updates from the same department.